|Therapeutic Candidate||Target||Trial Link||Trial Description|
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel in participants with refractory/recurrent esophageal, gastro-esophageal junction and gastric cancer
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer
|DKN-01||DKK1||NCT03645980||A Phase I/II Multicenter, Open-label Study of DKN-01 to Investigate the Anti-tumor Activity and Safety of DKN-01 in Patients With Hepatocellular Carcinoma and WNT Signaling Alterations|
|TRX518||GITR||NCT01239134||Study of TRX518 in Stage III or IV Malignant Melanoma or Other Solid Tumors|
|TRX518||GITR||NCT02628574||Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors|
Translating Cancer Research to Patients
Leap Therapeutics’ current clinical program includes product candidates targeting esophagogastric cancer, gynecologic cancer, biliary tract cancer, liver cancer, and other solid tumor malignancies. Details on our clinical trials are summarized below.
Leap Therapeutics has partnered with EmergingMed to help patients find clinical trials that match their specific cancer diagnoses and treatment histories. Please click here for Leap's Clinical Trial Navigation Service.